Ask Anything
Hot Research Today
Papers from every journal, all in one place. Create custom feeds.
RCT8 mentionsExpert CommentaryACC Journal Scan Highlight
JUL 13MahéCirculation
Prognosis of Recurrent Venous Thromboembolism During Extended Apixaban Therapy for Cancer-Associated Thrombosis: Insights From the API-CAT Randomized Trial
Randomized trial evaluates the prognosis of recurrent thromboembolism in cancer patients on apixaban, suggesting important treatment considerations.
DMDr. Marc Carrier
Professor, Ottawa Hospital Research Institute
Exciting results presented by Prof Isabelle Mahé at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, with simultaneous publication in Circulation. Key findings from this pre-specified ancillary analysis of the API-CAT trial include: Recurrent VTE during extended apixaban therapy was uncommon, occurring in only 2.5% of 1,766 patients over 12 months.
Guideline29 mentionsExpert CommentaryCirculation Highlight
JUN 29WalshCirculation
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
Standardizes pre-HF identification to enable targeted prevention; extends 2021 consensus for consistent research and surveillance.
AH
Guideline16 mentionsExpert CommentaryAHA Professional Heart Daily Highlight
JUL 9FlegCirculation
Exercise Training in High-Risk Populations: A Scientific Statement From the American Heart Association
Warrants individualized exercise regimens for high-risk groups; leaves open optimal protocols pending targeted trials.
GF
Guideline14 mentionsExpert CommentaryCirculation Highlight
JUN 24AdedinsewoCirculation
Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association
May inform perinatal HF care via expert consensus; leaves open standardized definitions and screening tools.
Guideline11 mentionsExpert CommentaryAHA Professional Heart Daily Highlight
JUL 8DiDomenicoCirculation
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association
Supports deprescribing assessment in CVD polypharmacy across ages; extends prior evidence beyond older adults to the full lifespan.
RCT · n=9484 mentionsTrending on XTrending on X
JUN 24TernacleJAMA Cardiology
TAVR shows similar 7-year rates of stage 2 or 3 SVD versus surgery in low-risk patients.
Supports comparable midterm valve durability for TAVR and surgery; leaves open need for extended follow-up data.
AJACC Journal Scan
For now, the PARTNER 3 trial durability analysis offers reassuring evidence of excellent midterm outcomes in low-risk patients. As TAVR continues to move into younger populations, understanding which durability pathways matter, and in whom, will be key to building effective lifetime valve strateg...
cohort · n=276,8881 mentionsExpert CommentaryACC Journal Scan Highlight
JUL 11FauchierEuropean Heart Journal
Influenza vaccination linked to a ~20% lower risk of incident AF versus no vaccination.
Influenza vaccination was associated with lower incident AF risk; supports hypothesis generation but should not yet change practice.
AJACC Journal Scan
...these findings support consideration of influenza vaccination as part of comprehensive cardiovascular and [AFib] prevention strategies in routine care.
Guideline1 mentionsExpert CommentaryFeatured in Podcast
JUL 1RizikКАРДИОЛОГИЯ УЗБЕКИСТАНА
SCAI/ASE/HRS/SIR/SVS Expert Consensus Statement on Enhanced Radiation Protection
Expert consensus calls for mandatory enhanced radiation protection in fluoroscopy labs, highlighting safety and regulatory needs.
cohort · n=55,7689 mentionsExpert CommentaryACC Journal Scan Highlight
JUL 1SanghviJournal of the American College of Cardiology
Higher sarcopenic obesity index linked to ~31% greater risk of incident heart failure and mortality.
Sarcopenic obesity indexing on routine CMR may refine risk stratification; leaves open whether targeting it improves outcomes.
AJACC Journal Scan
[Sarcopenic obesity] is emerging as a systemic cardiometabolic phenotype linking ageing, impaired muscle biology, heart failure vulnerability and frailty. By enabling scalable opportunistic quantification of muscle mass from routine CMR, Sanghvi et al., provide proof of concept that deep learning...
RCT · n=1,07913 mentionsTrending on XACC Journal Scan Highlight
JUL 1SotomiThe Lancet
One-month dual antithrombotic therapy is non-inferior to 12 months for major events in AF patients post-PCI.
1-month dual therapy noninferior with less bleeding after PCI in AF; extends abbreviated DAT evidence for this population.
DYDr. Yohei Sotomi
Cardiologist, University of Osaka Graduate School of Medicine
Patients with atrial fibrillation who receive a stent may only need 1 month of dual antithrombotic therapy, instead of 1 year. This shorter treatment is just as effective and much safer in terms of bleeding.